Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class ITerminatedD-1166-2022

Drug recall · July 6, 2022

Tegsedi recall

Why: Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).

Class I: a reasonable chance the product could cause serious harm or death.

The recall

Product

Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01

Lots / codes

Lots: 028C21AB, 028C21AC, Exp. 05/2025

Quantity
450 cartons
Company
Akcea Therapeutics, Inc., Carlsbad, CA
Distribution
KY, USA
Initiated
May 23, 2022 · Voluntary: Firm initiated
Classified
June 27, 2022
Reported
July 6, 2022
Ended
April 4, 2023
How notified
E-Mail

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.